ADMA Biologics (ADMA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.23
- Estimate
- $0.20
- Surprise
- +15.0%
- Revenue (period 2026-09-30)
- $141.1M
- Score at report (before → after)
- 6.2 → 6.0/10
Revenue source: xbrl.
How the report landed
ADMA Biologics (ADMA) beat the $0.20 estimate with adjusted EPS of $0.23 — a large 15.0% upside surprise. TrendMatrix's engine moved from Hold (6.2/10) to Buy (Wait) at 6.0/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ADMA Buy (Wait) at 6.1/10.
3 of the last 4 quarters beat the estimate; this quarter's +15.0% surprise compares with a +2.8% four-quarter average. Next scheduled report: 2027-02-24.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Weak growth
- News modifier +2: HOLD_IF_HOLDING → STRONG_BUY_WAIT
- Reward/Risk 0.9:1 at current price — below 1.5:1 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $12.79
- Entry target
- $12.06
- Price target
- $14.45
- Stop
- $11.22
- Upside to target
- +13.0%
- Reward-to-risk
- 0.9:1
The stock trades at 17.2× trailing but 14.0× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
ADMA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.96B
- P/E (fwd)
- 14.0
- P/E (ttm)
- 17.2
- 52-week range
- $7.21–$20.46
- Off 52-week high
- 37.5%
- RSI (14)
- 64
- Volume vs avg
- 0.41×
- Score today
- 6.1/10